The Outlook for Biotech in 2018

from The Bio Report · host Levine Media Group

We conclude our biotech review-preview series with our final installment this week as we take a look at the year ahead as the industry readies for the JPMorgan Healthcare Conference. We spoke to Jon Gardner, U.S. News Editor for EP Vantage, about the EP Vantage 2018 Preview(http://bit.ly/2CT2RDP), the outlook for big-value drug launches, and whether dealmaking or clinical success will drive stock prices in 2018. As a note, this podcast was recorded prior to Spark Therapeutics announcement of its pricing for its gene therapy Luxturna.

Episode metadata supplied by the publisher feed · Published Jan 4, 2018

Embed this episode

Attribution link and audio player

NOW PLAYING

The Outlook for Biotech in 2018

0:00 19:47

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Bio Report?

This episode is 19 minutes long.

When was this The Bio Report episode published?

This episode was published on January 4, 2018.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!